With one in five Americans experiencing clinical depression in their lifetime, should Google offer an online screening test for depression? Experts debate the issue in The BMJ today.
US based clinical psychiatrist Ken Duckworth says providing a screening test to people who are already seeking information online "could raise awareness to improve identification and treatment."
A Google search for "Am I depressed?" (or similar) via mobile phone will offer a link to the patient health questionnaire (PHQ-9) test - a screening tool used by doctors to monitor the severity of depression and response to treatment. Links to materials from the National Alliance on Mental Illness (NAMI) and telephone helplines will be offered with test results for people with higher scores.
He points out that this is not meant to replace clinical screening, nor does it constitute a universal screening program. Instead, "it is intended to prompt informed conversations with clinical professionals and to suggest potentially helpful resources."
And he stresses that the result alone cannot drive treatment without a professional making a formal diagnosis. Nor should it threaten privacy, as Google will not store or log any responses or results, or link these with individuals' other data.
"Increasing the motivated public's understanding of this validated screening tool could help to empower patients," he writes. "Informed people may have a better chance of getting the help they may need."
But Simon Gilbody, a clinician and professor of psychological medicine at the University of York UK, believes that unregulated screening for depression will be ineffective and worries if could cause harm.
He raises concerns over inadequate treatment resources to meet demand and assurances about privacy and misuse of data. "There are reasons to be concerned that data generated by a depression screening programme might be used to market antidepressants," he says.
He argues that depression should be diagnosed following a clinical assessment rather than a one-time screening test, warning that "episodes of transient (and self limiting) psychological distress will be confused with pervasive disorders that warrant treatment."
"Google's initiative has been reported positively and uncritically despite bypassing the usual checks and balances that exist for good reason. It is unlikely that their initiative will improve population health and may in fact do harm," he concludes.
This diagnostic tool focuses on physiological and biomedical symptoms, he writes. It puts firm emphasis on dysfunction and frames distress from the outset as an illness. He points to other ways to make a more meaningful diagnosis, but asks how much room might there be for this sort of dialogue if Google's approach spreads?
There is hope, he says, but change will happen only if service users have power and are equal partners with corporations like Google, so that decisions are made together. "Only then will online tools be a key that unlocks sense making, choice, and control."
More information: Should Google offer an online screening test for depression? www.bmj.com/content/358/bmj.j4144
Patient commentary: Online screening tests for depression: old (paternalistic) wine in new (digital) bottles, www.bmj.com/content/358/bmj.j4207
Provided by British Medical Journal